Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
Apr 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes |
Feb 2021 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors |
Feb 2021 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome |
Apr 2023 |
Blood Cancer |
Myelodysplastic Syndromes (MDS) |
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
Mar 2021 |
Blood cells, molecules and diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes |
Apr 2019 |
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
Current and emerging strategies for management of myelodysplastic syndromes |
Dec 2020 |
Blood reviews |
Myelodysplastic Syndromes (MDS) |